Shape Therapeutics
Seattle, Washington, United StatesSee on the mapFounded 2018
- Series B
Shape Therapeutics is a biotechnology company developing programmable RNA medicines to address the genetic causes of disease. It combines AI and RNA technology with drug development expertise to pursue new treatments.
- RaisedTotal raised
- $148M
- Jul 2021Latest priced round, Jul 2021
- Series B
- Investors
- 10
- Founded
- 2018
- Employees
- 51–200
reccy insights
Shape Therapeutics’ latest listed financing event is a grant dated Jul 29, 2026 from The Michael J. Fox Foundation for Parkinson's Research; no grant amount is specified. The company’s earlier major financing milestones were a $35.5M Series A announced on Nov 6, 2019, led by New Enterprise Associates, and a $112M Series B announced on Jul 15, 2021, led by Decheng Capital and Breton Capital Management. Those rounds brought in a broad investor group that also included Menlo Ventures, 8VC, Sofinnova Investments, Mission BioCapital, and CureDuchenne Ventures. Shape Therapeutics is developing programmable RNA medicines and describes RNAfix as an approach to correcting RNA without permanent DNA changes. No specific product launch, partnership announcement, award, or leadership change is included in the available company information, so there are few additional dated milestones to assess.
Written by reccy's AI from company sites, press and funding records · updated Nov 2026
What makes Shape Therapeutics distinct
- 01Combines AI and RNA technology to develop medicines targeting genetic causes of disease.
- 02Develops programmable RNA medicines and RNA editing technologies.
- 03Uses synthetic biology and engineered viral capsids to pursue targeted delivery.
- 04Brings together scientific, engineering, and drug-development expertise.
- 05Emphasizes inclusive collaboration, scientific integrity, and data-driven decisions.
Technology & products2
- RNAfix
RNA technology described as correcting RNA without permanent changes to DNA.
- Programmable RNA medicines
Medicines being developed to address genetic causes of disease using RNA technology, AI, and synthetic biology.
- RNAfix, described as correcting RNA without permanent DNA changes.
- AI-driven screening of genomic data to identify treatment possibilities.
- RNA editing technologies for programmable medicines.
- Engineered viral capsids and smart-sensing vector designs for targeted delivery.
- Scalable manufacturing technologies for RNA therapies.
Research roots1
Labs and research groups this company came from or works with.
- No page yetUniversity of California San DiegoSan Diego, United StatesSan Diego, United States · No page yetOther link
Funding
- GrantJul 2026The Michael J. Fox Foundation for Parkinson's Research
- Series BJul 2021$112MLed by Decheng Capital, Breton Capital Management, New Enterprise Associates, Ling Wong, Cherubic Ventures, Mission BioCapital, CureDuchenne Ventures, Joe von Rickenbach, Min Cui, Highbury Group, Sofinnova Investments, VZVC, Willett Advisors, 8VC, Menlo Ventures, Breton Capital Ventures
- Series ANov 2019$35.5MLed by New Enterprise Associates, Tectonic Capital, CureDuchenne Ventures, Ling Wong, Mission BioCapital
Investors18
- Tectonic Capital
- CureDuchenne Ventures
- Ling Wong
- Mission BioCapital
- Breton Capital Management
- Cherubic Ventures
- Joe von Rickenbach
- Min Cui
- Highbury Group
- Sofinnova Investments
- VZVC
- Willett Advisors
- Breton Capital Ventures
- The Michael J. Fox Foundation for Parkinson's Research
About Shape Therapeutics
- Products
- RNAfix, Programmable RNA medicines
- Leadership
- Francois VigneaultJohn SulimanPrashant Mali
- Focus areas
- RNA therapeutics, programmable RNA medicines, genetic disease, precision medicine, AI, drug development
- Headquarters
- Seattle, Washington, United States
- Founded
- 2018
- Employees
- 51–200
- Status
- Active · private